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Background: Campylobacter jejuni (C. jejuni) is the leading causative agent of bacterial gastrointestinal infections.
The rise of antibiotic resistant forms of this pathogen necessitates the development of novel intervention strategies.
One approach is the design of drugs preventing bacterial attachment to host cells. Although some putative C. jejuni
adhesins have been identified, the molecular mechanisms of their interaction with host cells and their role in
pathogenesis remain to be elucidated. C. jejuni adhesion may also be modulated by a bacterial capsule. However,
the role of this structure in adhesion was not clear due to conflicting results published by different research groups.
The aim of this study was to clarify the role of capsule in bacterial interaction with host cells by using an in vitro
model of adhesion and an analogue of a host cell receptor.
Results: In this study, we developed an in vitro bacterial adhesion assay, which was validated using various tests,
including competitive inhibition studies, exoglycosydase treatment and site-directed mutagenesis. We demonstrate
that PEB3 is one of the cell surface glycoproteins required for bacterial interaction with an analogue of a host cell
receptor. In contrast, JlpA glycoprotein adhesin is not required for such interaction. We demonstrate that the
production of capsule reduces bacterial attachment, and that the genes involved in capsule and PEB3 adhesin
biosynthesis are differentially regulated.
Conclusions: In this study we report an in vitro model for the investigation of bacterial interaction with analogs
of host cell receptors. The results suggest an interfering effect of capsule on bacterial attachment. In addition,
using a liquid culture, we demonstrate differential expression of a gene involved in capsule production (kpsM)
and a gene encoding a glycoprotein adhesin (peb3). Further studies are required in order to establish if
these genes are also differentially regulated during the infection process. The results will assist in better
understanding of the mechanism of pathogenesis of C. jejuni in general and the role of capsule in the
process in particular.
Keywords: Campylobacter, Adhesion, Attachment, Adhesins, Receptors, Glycoproteins, Glycosylation, MGL receptor,
C-type receptor, LectinsBackground
Campylobacter jejuni (C. jejuni), a microaerophilic, spiral-
shaped, flagellated Gram-negative bacterium, is the most
frequent cause of human gastroenteritis worldwide [1].
C. jejuni infections are often caused by consumption of
undercooked poultry, unpasteurised milk or contami-
nated water [2]. Adhesion of C. jejuni to host cells plays* Correspondence: a.karlyshev@kingston.ac.uk
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unless otherwise stated.an important role in colonisation of chickens and in hu-
man infection [3]. Campylobacter binding to host cell
receptors is not mediated by fimbria or pili, like in E.
coli and Salmonella [4]. As noted in a recent review,
other bacterial cell structures may contribute to interaction
of Campylobacter with host cells [5].
In some cases, bacterial adhesion can be mediated by
oligosaccharides present on the surface of host cells
[6,7]. In other cases, it is a pathogen oligosaccharide that
is responsible for binding to specific, lectin-like, host
cell structures. For example, a pathogenic Gram-positiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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(intelectin) expressed by cells in different organs including
intestine [8]. There is a possibility of similar lectin-glycan
interactions between host cells and Campylobacter. For
example, C. jejuni adhesion to Caco-2 cell receptors was
inhibited by certain lectins [9].
Campylobacter is capable of producing a variety of gly-
coproteins, some of which are cell-surface located [10].
Inactivation of the N-linked glycosylation system reduces
bacterial ability to adhere to epithelial cells and thereby
colonise the gastrointestinal tract [11,12]. These findings
suggest a possible role of some bacterial cell surface
surface-located bacterial N-linked glycoproteins in inter-
action with host cell receptors. Van Sorge and colleagues
[13] demonstrated interaction of N-linked glycoproteins
of C. jejuni with C-type lectins of Macrophage Galactose-
type lectins (MGL). In similarity with other pathogens, the
production of cell surface structures interacting with
C-type lectins may assist C. jejuni in the evasion of the
host immune response [14,15].
Another cell surface structure that may affect bacterial
interaction with host cell receptors is a capsular poly-
saccharide (CPS) [16-19]. Inactivation of the capsule
production machinery in strain 81–176 led to a two-
fold decrease in adhesion to INT407 cells [20]. Similar
findings were observed in another capsule deficient mu-
tant, 81116/kpsE [21]. However, these data were not
supported by complementation studies. Moreover, they
are in disagreement with other studies where the absence
of capsule showed increased adhesion of C. jejuni strain
11168H to Caco-2 cells [16]. The contradictory results
may be a consequence of differences in assay conditions,
bacterial strains and tissue cell lines.
In general, the capsules may play different roles in
bacterial attachment. This depends on the nature of a
bacterial pathogen, and on the structural features of
the capsules and adhesins. For example, F1 capsule of a
Yersinia pestis prevents fimbrial adhesins from interaction
with host cell receptors [22], while production of a capsule
by Neisseria meningitidis does not affect PilC1 adhesin-
mediated bacterial attachment [23].
In this study we developed and evaluated an in vitro
ELISA-like assay for the investigation of C. jejuni inter-
action with host cell receptors. The assay was successfully
used to study a role of capsule in attachment using SBA
(Soya bean agglutinin) lectin as an analogue of a host
cell receptor. In addition, using targeted mutagenesis
(supported by complementation analysis) we investigated
a role of PEB3 and JlpA adhesins in this interaction.
Furthermore, using real time PCR, we found that peb3
and a capsule-related gene are differentially expressed.
The results of these experiments suggest an interplay
between bacterial capsule and adhesins in interaction
with host cells.Results
Dose-dependent specific binding of C. jejuni cells to
immobilised SBA lectin
In order to investigate the mechanisms and factors
involved in C. jejuni interaction with host cells, we
developed an ELISA-like assay based on monitoring bac-
terial binding to immobilised analogues of host cell recep-
tors. In this model we explored the idea that some N-link
glycosylated proteins may be expressed on the bacterial
cell surface, and may potentially play a role of adhesins.
As glycan moieties in these glycoproteins contain terminal
GalNAc residues recognised by SBA, we used the latter as
an analogue of a host cell receptor.
Incubation of a suspension of C. jejuni 11168H cells
with immobilised SBA resulted in bacterial attachment
(Figure 1A). This binding was found to be specific as
demonstrated by inhibitory effects by both GalNAc and
a soluble form of SBA in a dose-dependent manner. The
inhibitory effect was detectable with as low concentration
of SBA lectin as 0.1 μM (Figure 1B). GalNAc also
showed an inhibitory effect at concentrations over 10 μM
(Figure 1C). Moreover, the bound cells could be detached
in the presence of a soluble form of lectin or GalNAc
(Figure 2). Further confirmation of specific binding
was obtained by treatment of bacterial cells with an
exoglycosidase. Removal of a terminal GalNAc resulted
in a remarkable reduction of the ability of bacterial
cells to attach (Figure 3).
In order to further confirm that the developed model of
attachment is specific and is based on the surface-located
GalNAc moieties, we repeated the binding experiments
using E. coli cells carrying the entire N-linked protein
glycosylation apparatus (pgl gene cluster) of C. jejuni
[24]. Due to the absence of glycosylation acceptor pro-
teins in strain E. coli XL2/pPGL1, the pgl system was
found to be able to glycosylate the bacterial lipo-
polysaccharide, resulting in exposure of GalNAc resi-
dues on the cell surface [24] (Figure 4A). The results
confirmed that E. coli XL2/pPGL1 cells are capable of
binding to immobilized SBA lectin in a GalNAc dependent
fashion (Figure 4B).
Expression of PEB3 is required for binding of C. jejuni
cells to immobilised SBA lectin
Previous studies suggested a possible location of PEB3
protein on a bacterial cell surface [25,26]. The purified
PEB3 protein was able to bind SBA lectin due to the pres-
ence of a GalNAc-containing glycan moiety [26]. In order
to confirm that attachment of C. jejuni cells to immobi-
lised SBA in our experiments is mediated by PEB3, we
constructed and investigated the binding properties of the
respective mutant. The results demonstrated significant
reduction of attachment of 11168H/peb3::kanr, which was
restored after complementation (Figure 5).
Figure 1 Interaction of C. jejuni with immobilised SBA. (A) C. jejuni
11168H interaction with SBA lectin is concentration dependent. The
figures below the bars indicate the numbers of cells per well. (B) Effect
of different concentrations of soluble SBA lectin on binding of C. jejuni
11168H. (C) Effect of different concentrations of GalNAc on binding of
C. jejuni 11168H.
Figure 2 Detachment of cells of C. jejuni 11168H in the presence
of 5 mM and 10 mM of soluble lectin (2 and 3 respectively), or
5 mM and 10 mM of GalNAc (4 and 5 respectively).
Figure 3 Reduction of binding upon treatment of bacteria with
GalNAc-specific exoglycosydase. Results with C. jejuni 11168H strain
(1 and 2) and its isogenic non-capsulated mutant 11168H/kpsM::kanr
(3 and 4) are presented. Samples before (1 and 3) and after (2 and 4)
treatment with exoglycosidase are shown. Elimination of capsule
increases bacterial attachment (1 and 3).
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mutation did not completely eliminate binding, suggesting
that other glycoprotein(s) may be involved in specific in-
teractions with this analogue of a host cell receptor. This
hypothesis was supported by reduction of the residual
binding of 11168H/peb3::kanr mutant in the presence of
soluble lectin (Figure 5).
One of the other cell surface-located proteins of C.
jejuni is JlpA, which was found to be an adhesinspecifically binding to heat shock protein 90 [27]. As
JlpA was also predicted to be an N-link glycosylated
protein [28], there was a possibility that it might be
responsible for residual binding of 11168H/peb3::kanr
mutant. To verify this hypothesis, we constructed a jlpA
mutant and tested the effect of this mutation on attach-
ment. Surprisingly, none of the three independent clonal
isolates showed any difference when compared with the
control recipient strain 11168H (data not shown) suggest-
ing the presence of other GalNAc-containing adhesins.
Production of capsule has a negative effect on binding
The results shown in Figure 3 also have demonstrated
a significantly higher efficiency of binding of the non-
capsular mutant of strain 11168H. These results, con-
firmed by analysis of three independent clonal isolates
of this mutant (data not shown), revealed significant
increase in binding upon inactivation of bacterial abil-
ity to produce capsule, suggesting an interfering effect
Figure 4 Interaction of E. coli cells, containing C. jejuni glycosylation gene cluster, with SBA lectin. (A) Confocal microscopy of E. coli XL2/
pPGL1 after treatment with fluorescently labelled SBA. No fluorescence was observed for E. coli XL2 control (data are not shown). (B) Attachment
of E. coli XL2/pPGL1 to immobilized SBA lectin (1) is inhibited by GalNAc at 5 mM (2). No binding of the recipient strain E. coli XL2 was
detected (3).
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receptors.
Peb3 and capsule-related genes are differentially expressed
Due to antagonistic effects of capsule and PEB3 adhesin
on bacterial attachment, we hypothesized that these
structures might be differentially expressed. To test thisFigure 5 Insertional inactivation of gene peb3 reduced the
ability of strain 11168H to bind immobilised lectin. 1, recipient
(11168H); 2, mutant (11168H/peb3::kanr ); 3, complementation
derivative (11168H/peb3::kanr/peb3+).hypothesis we conducted a comparative analysis of the
dynamics of kpsM and peb3 gene expression at different
growth stages in a liquid culture using real time PCR
(RT-PCR). The results showed a dramatic increase in
the level of peb3 gene expression at 48 hrs (Figure 6A),
whilst there was a reduction in kpsM gene expression after
24 hrs (Figure 6B).
Discussion
In this study, a model of bacterial attachment was devel-
oped. This model is based on monitoring bacterial binding
to immobilized analogues of host cell receptor. Although
we only tested attachment of Campylobacter jejuni to
SBA lectin, the method may have wider application for in-
vestigation of interaction of other bacteria with other host
cell receptors and their analogues.
The system was successfully tested by using C. jejuni
strain 11168H and its isogenic mutant 11168H/peb3.
Using the assay, we investigated interaction of bacteria
carrying cell surface located GalNAc residues with
immobilised SBA lectin. The binding was found to be
specific and dependent on the presence of soluble lectin
and GalNAc molecules, and was abolished by bacterial
deglycosylation. The study suggests the ability of C. jejuni
Figure 6 Increase of peb3 gene expression (A) and decrease
of kpsM expression (B) over time in a liquid culture. Gene
expression levels relative to 16S rRNA were determined as described
in Materials and Methods section.
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surface structures.
The SBA lectin used in this study shares binding spe-
cificity with C-type lectins (including MGL receptors)
produced by host cells. According to a recent study,
Campylobacter has the ability to interact with MGL re-
ceptors expressed on macrophages and dendritic cells
(DCs), which may modulate host immune response [13].
Human MGL receptors specifically recognise terminal
GalNAc residues [29,30]. Together with other C-type
lectins, the MGL receptors may be recognised by viruses,
e.g. a filovirus [31]. In addition, it was shown that MGL
recognizes a GalNAc containing antigen of a helminth
parasite Shistosoma mansoni [32]. Despite some data sug-
gesting a role of MGL receptors as a host defence factor,
the role of these molecules in C. jejuni infection is not
clear. However, there is a possibility that, via interaction
with MGL expressing macrophages and DCs this patho-
gen may subvert host immune response. It was suggested
that C. jejuni with functional MGL ligand (GalNAc) may
decrease IL-6 production by DCs [13].
Campylobacter have been known to produce a number
of N-glycoproteins, including PEB3 [33]. However, it was
still unclear which glycoprotein is reactive with MGL.
Our results demonstrated that peb3 mutation reduces
but does not completely eliminate binging, suggestingthe presence of other cell surface structures responsible for
attachment. Surprisingly, mutation in jlpA gene, encoding
another cell surface glycoproptein, had no effect on the
ability of C. jejuni to bind to the immobilized SBA lectin.
According to other studies, jlpA mutation also had no
effect on invasion of host cells [34,35].
An isogenic non-capsulated mutant 11168H/kpsM
showed an increase in binding indicating a negative effect
of capsule on bacterial attachment. In addition, results of
RT-PCR showed an increase of peb3 and a decrease of
kpsM gene expression over time, suggesting that a shield-
ing effect of capsule may be essential at the initial stages
of infection, hiding bacterial cell surface structures. Subse-
quent down regulation of CPS production during colon-
isation may lead to exposure of other bacterial cell surface
structures required for the attachment and/or evasion of
host immune response.
Conclusions
The results of this study demonstrated a complex inter-
play of Campylobacter capsule and glycoprotein adhesins
in pathogen-host interaction. The developed assay will as-
sist in more detailed investigation of such interaction and
in the development of inhibitors of attachment as novel
antibacterials.
Methods
Bacterial strains and growth conditions
C. jejuni strain 11168H and its isogenic mutant 11168H/
kpsM::kanr were described previously [19,36]. C. jejuni
was grown under microaerophilic conditions (5% O2,
10% CO2, 85% N2) at 37°C on Columbia Blood Agar
(Oxoid) containing 6% defibrinated horse blood (Fisher)
and Skirrow supplement (Sigma). Antibiotics (chloram-
phenicol 10 μg/ml and/or kanamycin 50 μg/ml) were added
to the media as required. E. coli strains XL1 and XL2
(Stratagene) were used in cloning experiments. E. coli
strains were maintained on Luria–Bertani agar (Oxoid)
plates or in Luria–Bertani broth (Oxoid) supplemented
with appropriate antibiotics (ampicillin 100 μg/ml, kana-
mycin 50 μg/ml or chloramphenicol 34 μg/ml) at 37°C.
General cloning techniques
Molecular cloning was performed using standard proto-
cols. The plasmids used in this study are listed in Table 1.
Restriction enzymes and antarctic phosphatase were
purchased from New England Biolabs. T4 DNA ligase
and T4 DNA polymerase were purchased from Promega.
Oligonucleotides were ordered from Sigma-Genosys.
Genomic and plasmid DNAs were extracted using Qiagen
kits. Restriction, DNA ligation, dephosphorylation and
blunt-ending were performed according to manufacturers’
protocols.
Table 1 Plasmids used in this study
Plasmids Description Source (reference)
pGEM-T Easy Cloning vector Promega
pJMK30 Source of kanr cassette [37]
pAV35 Source of camr cassette [37]
pBAD33 Contains pBAD promoter [38]
pPGL1 C. jejuni 16 kb fragment,
containing pgl gene cluster,
cloned into pBR322
[24]
pRRC Cassette cloned into pRR
(fragment of rRNA gene cluster
cloned into pGEM-T easy)
[39]
Table 3 Primers used for RT-PCR
Primer name Primer sequence (5′-3′) Used for
q-16 s-for ACAGGTGCTGCACGGCTGTC Control
q-16 s-rev TGCTCGGCCGAACCGTTAGC Control
Peb3_qpcr_for GCATCGGCTTGATCTTGTGCG peb3 expression
Peb3_qpcr_rev CGTTGTGCCTGAAGGTGCTGG peb3 expression
kpsM_qpcr_for GCCTGAGTTCCATTCATAAGCTGGG kpsM expression
kpsM_qpcr_rev TGGGTAGTTGGGGAGCCTATGAG kpsM expression
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Fragments of the genes peb3 and jlpA were PCR ampli-
fied using the primers listed in Table 2 and cloned into
pGEM-T Easy (Promega) vector to produce plasmids
pGEM_peb3 and pGEM_jlpA respectively. In order to
disrupt the peb3 gene, the pGEM_peb3 plasmid was
digested with PflMI, blunt ended and ligated with the
SmaI-digested kanr cassette producing pGEMpeb3_kan
construct. The jlpA gene was disrupted by insertion of
the XbaI-digested camr cassette (isolated from pAV35,
Table 1) into the BsaBI restriction site of pGEM_jlpA
plasmid, yielding pGEM_jlpA_cam. In both cases the
orientation of the antibiotic resistance cassette was the
same as that of the target gene to avoid a negative polar
effect in the mutants. Mutagenesis using the constructed
derivatives was conducted via electroporation and se-
lection of the derivatives on media supplemented with
appropriate antibiotics. Allelic replacement was confirmed
by PCR. The mutants were designated 11168H/peb3::kanr
and 11168H/jlpA::camr.
Complementation of peb3 mutant
Peb3 gene was PCR amplified using primers described in
Table 1. The product was digested with XbaI enzyme
and cloned into XbaI-digested pRRC plasmid to produce
pRRC_peb3. Restriction analysis verified that the gene
was transcribed in the same orientation as the camr gene.
After transformation of the 11168H/peb3::kanr mutant
with plasmid pRRC_peb3, KanrCamr clones were selected.Table 2 Primers used for mutation of peb3 and jlpA and for c
Primer Sequence (5′-3′)
peb3_for ATGAAAAAAATTATTACTTTATTTGGTGCATG
peb3 _rev TTATTCTCTCCAGCCGTATTTTTTAAAAATTTC
jlpA_for ATGAAAAAAGGTATTTTTCTCTCTATTGG
jlpA_rev TTAAAATGACGCTCCGCCCATTAACATAG
peb3_XbaI_for ATAATCTAGAAAGGAAATACTATGAAAAAAATTATTACT
Peb3_XbaI_rev AGGTTCTAGATTAATGATGATGATGATGATGTTCTCTCCAPCR analysis confirmed integration of peb3 gene into one
of the rRNA gene clusters. The complementation deriva-
tive was designated 11168H/peb3::kanr/peb3+.
Binding assay
Bacterial attachment was studied in ELISA-like assay
using a 96-well microtiter plate Maxisorp™ (Thermo
Scientific) coated Soya Bean Agglutinin (SBA) lectin
(Sigma) in bicarbonate-coating buffer: 5.3 g/L Na2CO3,
4.2 g/L NaHCO3, 1 g/L sodium azide, pH 9.6.
Microtiter plate wells were incubated overnight with
SBA lectin (10 μg/ml) at 4˚C, followed by blocking with
1% Bovine Serum Albumin (BSA) overnight at 4°C. BSA-
coated, wells were used as negative control. Bacteria
(two-day cultures of C. jejuni or one-day cultures of E.
coli) were harvested, resuspended in Phosphate-Buffered
Saline (PBS) to OD600 = 1, 0.1 ml suspensions (corre-
sponding to 4x108 c.f.u. of C. jejuni) were added to each
well of the microtiter plate, followed by incubation for
40 min at room temperature. After rinses with PBS, sup-
plemented with 0.2% Tween (PBST) the plate was incu-
bated with biotinylated SBA lectin (Vectors Laboratories)
for 60 min at room temperature. The wells were then
treated with horseradish peroxidase-conjugated streptavi-
din (Sigma) for 30 min at room temperature followed by
incubation with TMB (3,3′,5,5′-Tetramethylbenzidine)
substrate (Sigma) for 10 min. The reaction was stopped by
adding stop solution (1 M H2SO4). Binding was monitored
by measuring OD at 450 nm. For inhibition studies,
the plates were treated with bacterial suspension in the
presence of SBA lectin or GalNAc (Sigma) at different
concentrations. Detachment was carried out by additionomplementation of peb3
Used for
Mutation of peb3 gene
Mutation of peb3 gene
Mutation of jlpA gene
Mutation of jlpA gene
TTATTTGGTGC Complementation of peb3 mutation
GCCGTATTTTTTAAAAATTTC Complementation of peb3 mutation
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lectin or GalNAc, followed by incubation for 40 min at
room temperature.
Fluorescein SBA (FSBA) labelling of C. jejuni and E.coli cells
Fluorescein labelling of cells was done as described previ-
ously [40]. FSBA (Vector Laboratories) (100 μg/ml in PBS)
was mixed with an equal volume of bacterial suspension
and incubated for 40 min at room temperature. Bacteria
were pelleted, washed twice in PBS to remove any unbound
lectin. Samples were observed by fluorescence microscopy
using a laser scanning confocal microscope (Leica TCS SP2
AOBS) with a 63X immersion objective.
Treatment with exo-glycosidase
In order to remove GalNAc residues bacterial cells were
treated with 20 U of N-acetylgalactosaminidase (NEB) for
60 min at 37°C according to manufacturer’s protocol.
RNA isolation and RT-PCR
For RNA isolation, C. jejuni cells were grown for
48 hours under microaerophilic conditions (5% O2, 10%
CO2, 85% N2) at 37° in three separate flasks (biological
replicates) in Brain Heart Infusion Broth (Oxoid). Sam-
ples for RNA isolation were taken at 14 h, 24 h, 38 h
and 48 h intervals. Immediately after taking the samples
from the flasks RNAprotect Bacteria Reagent (Qiagen)
was added to the cultures to stabilize mRNA. The total
RNA from each sample was extracted using the RNeasy
Mini Kit (Qiagen). The purified RNA samples were
treated with On-Column DNaseDigestion Kit (Qiagen)
followed by treatments with DNase in order to remove
residual DNA contamination. RNA concentration was
estimated using NanoDrop ND-1000 spectrophotom-
eter (NanoVue). The quality and integrity of total RNA
was monitored using the Agilent 2100 Bioanalyzer
(Agilent Technologies).
RT-PCR was used for gene expression studies of peb3
and kpsM using primers listed in Table 3. Primers were
designed from C. jejuni DNA sequences using NCBI web
server (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
In addition, potential secondary structures and primer
dimer formation were verified using an on-line tool,
Sigma-Genosys DNA calculator. Primers were purchased
from Sigma Genosys Ltd. One-step RT-PCRs were per-
formed in triplicate by using QuantiFast SYBR Green RT-
PCR Kit (Qiagen). The RT-PCR reaction was performed
in a total volume of 12.5 μl, containing 6.25 μl master
mix and 0.25 RT mix, consisting of 1 μl forward pri-
mer, 1 μl reverse primer 3.6 μl diluted RNA (50 ng)
and 6.25 μl water. Primers were added to 100 μM final
concentration. Each sample was analysed in technical
duplicates and biological triplicates.The cycle parameters were as follows: an initial reverse
transcription step for 10 min at 50°C, and then PCR
initial activation step for 5 min at 95°C followed by
two-step cycling: denaturation at 95°C for 10 s and
combined annealing 60°C for 30 sec. The number of
cycles was 35. The changes in gene expression (n-fold)
calculated from the qRT-PCR data. Analysis of relative
gene expression data was done using the 2-2ΔΔCT method
as described previously [41]. The 16S rRNA was used as
the internal controls.
Statistical analysis
All experiments were repeated a minimum of three times,
and data are expressed as mean ± SD. Differences were
considered significant for P < 0.05 (*, P value 0.05-0.01; **,
P value <0.01). Comparison of two groups was made with
an unpaired, two-tailed student’s t-test. Comparison of
multiple groups was made with ANOVA.
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